Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib + Camrelizumab + Fruquintinib in metastatic colorectal cancer after failure of second-line or later therapy
ChiCTR2600128602Phase 2Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib, camrelizumab and fruquintinib in colorectal cancer (CRC), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: Objective response rate and Adverse events and serious adverse events. Started Jul 2026; status: recruiting.
02
Drugs
ivarmacitinibcamrelizumabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600128602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128602.